Results 11 to 20 of about 44,840 (262)

Clostridioides difficile infection: are the three currently used antibiotic treatment options equal from pharmacological and microbiological points of view?

International Journal of Infectious Diseases, 2022
Recently, the recommendations for the treatment of Clostridioides difficile infection (CDI) have been updated. However, in addition to the clinical efficacy data, the drug of choice should ideally represent optimal antimicrobial stewardship, with an ...
Marcela Krutova, Mark Wilcox, Ed Kuijper
doaj   +1 more source

Variants at the MHC Region Associate With Susceptibility to Clostridioides difficile Infection: A Genome-Wide Association Study Using Comprehensive Electronic Health Records

Frontiers in Immunology, 2021
BackgroundClostridioides difficile is a major cause of healthcare-associated and community-acquired diarrhea. Host genetic susceptibility to Clostridioides difficile infection has not been studied on a large-scale.MethodsA total of 1,160 Clostridioides ...
Jiang Li, Yanfei Zhang, Alexandria L. Jilg, Donna M. Wolk, Harshit S. Khara, Amy Kolinovsky, David D. K. Rolston, Raquel Hontecillas, Josep Bassaganya-Riera, Marc S. Williams, Vida Abedi, Ming Ta Michael Lee   +11 more
doaj   +1 more source

SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection.

New England Journal of Medicine, 2022
BACKGROUND Current therapies for recurrent Clostridioides difficile infection do not address the disrupted microbiome, which supports C. difficile spore germination into toxin-producing bacteria.
P. Feuerstadt, T. Louie, B. Lashner, E. Wang, Liyang Diao, J. Bryant, M. Sims, Colleen S Kraft, Stuart H. Cohen, C. Berenson, L. Korman, Christopher B. Ford, Kevin D Litcofsky, M. Lombardo, J. Wortman, Henry Wu, J. Auniņš, Christopher McChalicher, J. Winkler, B. McGovern, M. Trucksis, M. Henn, L. V. von Moltke   +22 more
semanticscholar   +1 more source

Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection

Drugs, 2022
Recurrent Clostridioides difficile infection, associated with dysbiosis of gut microbiota, has substantial disease burden in the USA. RBX2660 is a live biotherapeutic product consisting of a broad consortium of microbes prepared from human stool that is ...
S. Khanna, M. Assi, Christine Lee, David L. Yoho, T. Louie, W. Knapple, H. Aguilar, J. Garcia-Diaz, Gary P. Wang, S. Berry, Joe Marion, Xin Su, Tricia L. Braun, Lindy L. Bancke, P. Feuerstadt   +14 more
semanticscholar   +1 more source

Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI

BMC Infectious Diseases, 2021
Clostridioides difficile is a Gram-positive anaerobic bacterium, which causes Clostridioides difficile infection (CDI). It has been recognised as a leading cause of healthcare-associated infections and a considerable threat to public health globally ...
Elaine Finn, F. Andersson, M. Madin-Warburton   +2 more
semanticscholar   +1 more source

Epidemiology of Clostridioides difficile Infection in Portugal: A Retrospective, Observational Study of Hospitalized Patients

Acta Médica Portuguesa, 2022
Introduction: Clostridioides difficile is the main cause of healthcare-associated diarrhea in Europe and North America. The aim of this study was to characterize the epidemiology and clinical burden of Clostridioides difficile infection among ...
Cláudia Nazareth, Inês Leitão, Ernestina Reis, Hugo Inácio, Filomena Martins, Elmano Ramalheira, Flávia Cunha, Carla Santos, Sara Lino, Hugo Moreira, Nadiya Kruptsala, Andrea Santos, Laura Paixão, Leonor Pássaro, Mónica Oleastro   +14 more
doaj   +1 more source

VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial.

Journal of the American Medical Association (JAMA), 2023
Importance The effect of rationally defined nonpathogenic, nontoxigenic, commensal strains of Clostridia on prevention of Clostridioides difficile infection (CDI) is unknown.
T. Louie, Y. Golan, S. Khanna, D. Bobilev, Nathalie Erpelding, Candida Fratazzi, M. Carini, Rajita Menon, Mary M. Ruisi, J. Norman, J. Faith, B. Ollé, Minran Li, J. Silber, D. Pardi   +14 more
semanticscholar   +1 more source

IL-27 induces LL-37/CRAMP expression from intestinal epithelial cells: implications for immunotherapy of Clostridioides difficile infection

Gut Microbes, 2021
Clostridioides difficile infection is currently the leading cause of nosocomial antibiotic-associated diarrhea and pseudomembranous colitis worldwide. Cathelicidins, a major group of natural antimicrobial peptides, have antimicrobial and immunomodulatory
Banglao Xu, Xianan Wu, Yi Gong, Ju Cao
doaj   +1 more source

Clostridioides difficile Infection [PDF]

Annals of Internal Medicine, 2018
Clostridioides difficile (formerly Clostridium difficile) infection is the most frequently identified health care-associated infection in the United States. C difficile has also emerged as a cause of community-associated diarrhea, resulting in increased incidence of community-associated infection.
Alice Y, Guh, Preeta K, Kutty
openaire   +2 more sources

Does Fecal Microbiota Transplant Have a Role in Treating Recurrent Clostridioides difficile Infection in Rural Hospitals?

Frontiers in Public Health, 2021
Clostridioides difficile infection possesses a significant economical burden, specifically in the inpatient and rural settings. Fecal Microbiota Transplant has been used for treatment of recurrent Clostridioides difficile but its utility is limited by ...
Krishna Vedala, Philip Sobash, Parth Shah, Gilbert-Roy Kamoga   +3 more
doaj   +1 more source